Ketamine, administered intravenously in low doses, rapidly reduces suicidal ideation in patients with Borderline Personality Disorder (BPD) and Major Depressive Disorder (MDD). Its mechanism likely involves regulation of neurotrophic factors. The drug also alleviates mood dysregulation and impulsive behavior in BPD. Despite these benefits, further research is needed to determine optimal dosing, safety, and contraindications before it can revolutionize emergency management of suicidality.
Psilocybin, a psychedelic compound from certain mushrooms that acts on serotonergic receptors (primarily 5HT-2A), is emerging as a viable treatment option for Major Depressive Disorder (MDD) and treatment-resistant depression. Studies have demonstrated its effectiveness for these conditions. The FDA granted 'breakthrough' therapy status to a psilocybin treatment developed by Compass Pathways Ltd.